期刊文献+

胺碘酮联合阿托伐他汀对兔心肌梗死模型心脏MAPD90、VFT的影响 被引量:5

下载PDF
导出
摘要 目的观察胺碘酮联合阿托伐他汀对兔心肌梗死模型心肌动作电位时限复极90%的时间(MAPD90)和室颤阈值(VFT)的影响。方法将24只日本大耳白兔随机分为观察组、模型组和对照组各8只,观察组和模型组采用结扎前降支动脉法建立心肌梗死模型,对照组不予处理。观察组于术后第1天开始以50 mg/(kg·d)胺碘酮+3 mg/(kg·d)阿托伐他汀灌胃,模型组和对照组均给予等量生理盐水,1次/d,连续8周。利用LEAD 2000B 32道生理记录仪检测MAPD90、VFT。结果观察组、对照组、模型组左心室外膜层MAPD90均依次降低,观察组、对照组左心室内膜层、中膜层MAPD90及单相MAPD90、VEF均高于模型组,P均<0.05。结论胺碘酮、阿托伐他汀联合应用可延长兔心肌梗死模型心脏MAPD90,并提高VFT。
出处 《山东医药》 CAS 北大核心 2015年第16期24-25,共2页 Shandong Medical Journal
基金 国家重点基础研究发展计划(2012CB518604) 湖北省自然科学基金资助项目(2013CFA117 2013CKB005)
  • 相关文献

参考文献1

二级参考文献22

  • 1Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495-1504.
  • 2LaRosa JC, Grundy SM, Waters DD, et al; Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425-1435.
  • 3Pedersen TR, Faergeman O, Kastelein J J, et al; Incremental Decrease in End Points Through Aggressive Lipid Lowedng (IDEAL) Study Group. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study:a randomized controlled trial. JAMA. 2005;294:2437-2445.
  • 4Grundy SM, Cleeman JI, Merz CN, et al; Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel Ⅲ Guidelines. J Am Coll Cardiol. 2004;44:720-732.
  • 5Blankenhom DH, Azen SP, Kramsch DM, et al;MARS Research Group. Coronary angiographic changes with Iovastatin therapy: the Monitored Atherosclerosis Regression Study (MARS). Ann Intern Med.1993;119:969-976.
  • 6Waters D, Higginson L, Gladstone P, et al. Effects of monotherapy with HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed be serial quantitaUve arteriography: the Canadian Coronary Atherosclerosis Intervention Trial(CCAIT). Circulation. 1994;89:959-968.
  • 7Jukema JW, Bruschke AV, van Boven A J, et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels: the Regression Growth Evaluation Statin Study (REGRESS). Circulation. 1995;91:2528-2540.
  • 8Pitt B, Mancini GB, Ellis SG, Rosrnan HS, Park J-S,McGovem ME. Pravastatin limitaUon of atherosclerosis in the coronary arteries (PLAC Ⅰ): reduction in atherosclerosis progression and clinical events. J Am Coll Cardiol. 1995;26:1133-1139.
  • 9Brown G, Albers J J, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipidlowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 1990;323:1289-1298.
  • 10MAAS Study Group. Effect of simvastatin on coronary atheroma: the Multicentre Anti-atheroma Study( MAAS). Lancet. 1994;344:633 -638.

共引文献342

同被引文献15

引证文献5

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部